Association between vascular adhesion protein-1 and major adverse cardiovascular events in heart failure patients: a retrospective cohort analysis Authors: You Zhang, Chi Geng, Feng Li, Mengchao Jin, Siliang Peng, Zhiyuan Zhang, Xiaosong Gu, Jing Li, Hui Li Published: 2026 ABSTRACT BackgroundVascular adhesion protein-1 (VAP-1), a multifunctional inflammatory mediator, has been implicated in cardiovascular pathology. Current evidence regarding its prognostic relevance in heart failure (HF) is incomplete. This investigation was designed to evaluate circulating VAP-1 as a biomarker for its association with HF progression susceptibility and its clinical prognostic value for adverse cardiovascular events.MethodsThis retrospective observational cohort study included 356 individuals receiving treatment at Soochow University Hospital from May 2020 to September 2022, among whom 165 were diagnosed with heart failure. During the baseline evaluation, VAP-1 concentrations in blood serum were measured through ELISA testing. Major adverse cardiovascular events (MACE) were designated the principal study endpoints, with data collected from electronic health records and telephone follow-ups. Analytical methods incorporated multiple regression analysis, nonlinear modeling approaches, and Kaplan-Meier survival probability assessments. Additional analyses examined the association between heart failure progression and VAP-1 levels through multiple regression modeling, ROC curve assessment, and AUC calculations to establish VAP-1’s diagnostic potential for heart failure identification.ResultsWhen accounting for potential confounding factors, higher concentrations of VAP-1 showed a correlation with MACE in patients with HF (Q2 versus Q1: hazard ratios [HR] = 1.7, 95% confidence intervals [CI] = 0.71–4.12; Q3 versus Q1: HR = 2.85, 95% CI = 1.1–7.36). These results were further validated through survival probability assessments and non-linear regression modeling. Multiple regression analysis demonstrated that increased VAP-1 levels served as an independent risk factor for heart failure progression (P = 0.0271, HR = 1.0012, 95% CI = 1.0001–1.0022).ConclusionsThe study demonstrates a meaningful relationship between heightened VAP-1 concentrations and both the development of heart failure and cardiovascular complications, indicating VAP-1’s possible utility as a diagnostic marker for assessing heart failure risk and clinical outcomes.Supplementary InformationThe online version contains supplementary material available at 10.1186/s12872-026-05935-1. Introduction Heart failure (HF) represents the final phase of multiple cardiovascular disorders, exhibiting widespread occurrence worldwide alongside consistently elevated fatality and hospitalization rates [1–3]. As demographic shifts toward older populations, the burden of HF is progressively escalating. The underlying pathology involves myocardial remodeling, driven by complex molecular and cellular mechanisms [4]. Crucially, immunological and inflammatory responses play pivotal roles in disease progression [5]. Despite this understanding, existing treatments targeting inflammation have shown limited clinical effectiveness in heart failure management [6], highlighting the urgent requirement for discovering novel therapeutic approaches that can effectively modulate inflammatory pathways. In the search for better risk stratification, recent studies have highlighted the prognostic value of composite biomarkers reflecting systemic inflammation, endothelial stress, and nutritional status in HF [7–9]. This underscores the ongoing need to identify and validate circulating biomarkers that capture key pathophysiological processes in HF. Vascular adhesion protein-1 (VAP-1), also known as semicarbazide-sensitive amine oxidase (SSAO), is a dual-function molecule that combines cell adhesion properties and enzymatic oxidase activity [10]. VAP-1 exists in both a membrane-bound form, expressed on the surface of various cell types including vascular endothelial cells, and a soluble form (sVAP-1) released into the circulation via proteolytic cleavage. Both isoforms are biologically active. The protein uniquely combines vascular adhesive properties with enzymatic amine oxidase activity, a dual functionality central to its roles in orchestrating leukocyte trafficking and promoting vascular inflammatory damage [11]. VAP-1 is implicated in the pathogenesis of a wide range of diseases, including inflammatory, metabolic, fibrotic, and neoplastic disorders. Consequently, circulating sVAP-1 has emerged as a promising diagnostic and prognostic biomarker in several clinical contexts. Additionally, growing scientific data suggests that sVAP-1 serves as a valuable diagnostic and predictive marker for numerous disease states, with clinical trials confirming its potential utility as a biological indicator [12]. Scientific studies have established a clear correlation between circulating sVAP-1 levels and various cardiovascular disorders, including atherosclerosis, stroke, and coronary artery disease [13–15]. Numerous research projects have identified a connection between increased sVAP-1 concentrations and the development as well as advancement of atherosclerotic processes, as evidenced by detailed evaluations of vascular characteristics like carotid intima-media thickness, plaque size measurements, arterial elasticity indices, and calcific valve disease [16–18]. Pharmacological VAP-1 inhibition has been shown to attenuate both atherosclerotic progression and myocardial ischemia-reperfusion injury in animal models. For instance, the specific inhibitor PXS4728A reduced plaque formation in hypercholesterolemic rabbits and improved vascular function in ApoE-deficient mice [19, 20]. The protective effect is likely mediated by inhibiting leukocyte adhesion and migration [21]. Patients with coronary artery disease (CAD) exhibit elevated circulating levels of sVAP-1, which correlate with disease progression. Increased sVAP-1 concentrations are associated with a higher risk of major adverse cardiovascular events (MACE) and cardiac mortality [22–24]. Consistent with this, our study evaluating sVAP-1 for its prognostic value in CAD confirmed that elevated levels are an independent predictor of adverse cardiovascular outcomes [25]. Similarly, in heart failure (HF), patients exhibit elevated sVAP-1 levels, which correlate with disease severity and serve as an independent predictor of mortality in chronic HF [26–28]. Nevertheless, the available investigations in this domain remain scarce, somewhat dated, and have predominantly examined the relationship between VAP-1 concentrations and particular heart failure subtypes. In contrast to the recent validation of other inflammatory and systemic stress biomarkers [7–9], a comprehensive evaluation of sVAP-1’s prognostic utility, particularly in relation to HF progression and MACE, is still lacking. Consequently, the current investigation was designed to systematically review and evaluate clinical records from HF patients to clarify the relationship between sVAP-1 concentrations and the likelihood of HF progression. Additionally, the study sought to examine the connection between sVAP-1 and MACE, ultimately determining VAP-1’s potential as both a diagnostic marker and prognostic indicator in heart failure cases. Methods Study design and participants This study examined the medical records of patients treated at the Cardiology Department of the Second Affiliated Hospital of Soochow University between May 2020 and September 2022. The inclusion criteria were as follows: (1) Individuals aged over 18 years; (2) Patients were included if they had been diagnosed with either acute or chronic HF by a cardiology specialist, either during the present hospital admission or through previous medical assessments. The diagnostic process involved comprehensive evaluation of medical records, physical assessments, laboratory tests, and sophisticated cardiac imaging techniques. Key exclusion criteria encompassed several major comorbidities: significant valvular disorders (including moderate-to-severe stenosis or regurgitation); end-stage renal failure requiring dialysis; any current, active malignant tumor; and confirmed acute infections of the lower respiratory system (as illustrated in Fig. 1). Ethical approval for this study was granted by​ the Ethics Committee at Soochow University’s Second Affiliated Hospital (Reference Number: JD-LK-2022-125-01). Prior to data processing, all patient identifiers were removed to ensure confidentiality. This research was performed in full compliance with​ the ethical standards established by the Declaration of Helsinki (2013 version) . Fig. 1Flowchart of participant selection. Abbreviations: VAP-1 = Vascular adhesion protein-1; HF = heart failure Flowchart of participant selection. Abbreviations: VAP-1 = Vascular adhesion protein-1; HF = heart failure Measurement of sVAP-1 concentration The research employed plasma specimens obtained from leftover samples gathered during initial hospital laboratory examinations to measure VAP-1 levels. Prior to enrollment, each subject signed documentation authorizing the use of their biological materials for scientific research purposes in compliance with institutional guidelines. Following a minimum 12-hour fasting period, venous blood was drawn and immediately stored at ultra-low temperatures (-80 °C) for subsequent analysis. Serum VAP-1 concentration was measured by​ a commercial ELISA kit (BMS259TEN, Invitrogen, USA), in accordance with​ the established protocols for sample processing and analysis [25]. Covariates This study integrated​ two primary data sources: electronic medical records and structured telephone interviews, comprising detailed patient information on demographic characteristics, comorbid conditions, personal histories, vital signs, and laboratory findings. The baseline assessment captured essential demographic and clinical data from all participants. This included the standard demographic metrics of sex, age, and body mass index. Furthermore, the clinical history accounted for relevant comorbidities, encompassing conditions from atrial fibrillation to chronic obstructive pulmonary disease. Measurements of systolic and diastolic blood pressure, as well as heart rate, were also taken at admission. A comprehensive set of laboratory parameters was analyzed from blood samples obtained on the first day. The complete blood count encompassed​ an analysis of key hematological parameters, including leukocyte subpopulations (neutrophils, lymphocytes, monocytes) and platelet counts. A panel of tests was performed, which quantified levels of hemoglobin, C-reactive protein, and renal functional parameters, including serum creatinine (SCr), blood urea nitrogen (BUN), and uric acid; the estimated glomerular filtration rate (eGFR) was subsequently derived from these measurements. The metabolic assessment evaluated​ two primary categories: lipid metabolism, comprising​ triglycerides (TG), total cholesterol (TC), HDL, VLDL, and LDL; and glucose homeostasis, assessed via fasting blood glucose and glycated hemoglobin A1c (HbA1c). Liver function was evaluated via enzymes (ALT, AST [aspartate aminotransferase]) and bilirubin levels (total, indirect), alongside serum albumin. Laboratory assessments further comprised​ a panel of​ electrolytes (sodium, potassium, chloride), along with specific enzymes and cardiac markers, including creatine kinase (CK), cardiac troponin T (cTnT), and N-terminal pro-B-type natriuretic peptide (NT-proBNP) and D-dimer. Cardiac structure and function were assessed echocardiographically using a GE Vivid E9 system with an M5S phased array transducer (2.0–4.5 MHz). With patients in the left lateral decubitus position, images were acquired from the parasternal view. Left ventricular ejection fraction (LVEF) was determined using the modified Simpson’s rule from apical 4- and 2-chamber views. Left atrial diameter (LAD) and left ventricular end-diastolic dimension (LVDD) were also documented [29]. All the echocardiographic assessments were performed by a single experienced echocardiographer [29]. Outcomes The main research objective centered on MACE, which encompassed various cardiovascular outcomes including death from cardiovascular causes, acute myocardial infarction, non-heart attack acute coronary events, stroke-related incidents, and worsening heart failure episodes necessitating hospital admission. Furthermore, the investigation explored the relationship between VAP-1 and HF within China’s demographic context, without consideration of NYHA functional classification, acute decompensation condition, or specific categories of left ventricular dysfunction identified through cardiac ultrasound examination. Statistical analysis Categorical variables were presented as numerical frequencies along with corresponding percentages. Continuous variables following a normal distribution were reported using arithmetic means accompanied by standard deviation values, while non-normally distributed measurements were described through median figures with their respective interquartile ranges. For comparing categorical measures, the Pearson χ² test was employed. Continuous parameters were analyzed either through one-way ANOVA when normally distributed or through nonparametric rank-based methods for skewed distributions. The relationship between VAP-1 and major adverse cardiovascular events was evaluated through multivariate Cox regression analyses, conducted across the entire cohort as well as specifically within the heart failure patient subgroups. The statistical methodology included both unadjusted and covariate-adjusted model specifications. Clinically relevant candidate confounders were assessed using a structured selection process: each covariate was individually added to a core model containing only VAP-1, and was retained for the final multivariable model if its inclusion altered the hazard ratio (HR) for VAP-1 by more than 10% compared to the crude estimate. Multicollinearity among selected variables was examined using the variance inflation factor (VIF), with a VIF ≥ 5 indicating its presence. Model building proceeded sequentially: Model I adjusted for age and sex; Model II incorporated additional significant covariates from prior screening; and Model III included variables that were both statistically significant and clinically meaningful. The functional form of the VAP-1–MACE association was illustrated with restricted cubic splines. For survival analysis, researchers employed Kaplan-Meier methodology, with statistical comparisons between mortality rates across different groups performed using log-rank tests. To further examine the dose-response relationship, investigators applied piecewise linear regression analysis alongside multivariate modeling and curve fitting results, aiming to detect possible critical values of VAP-1 levels that might influence cardiovascular outcomes in heart failure patients. For continuous variables with minimal missing data (< 6%), multiple imputation by chained equations (MICE) was employed. The distributions of key variables were compared before and after imputation, revealing no substantial differences (Supplementary Tables 1–2). All statistical computations were conducted using Free Statistics software (v2.0) in conjunction with R version 4.4 (available at http://www.R-project.org; maintained by The R Foundation). For hypothesis testing, we adopted a conventional significance level of P < 0.05 with two-tailed evaluation. Results Clinical characteristics of the patient cohort The research project commenced with 356 potential subjects, from which 20 individuals were subsequently removed from consideration. This exclusion was based on three primary medical conditions: significant valvular disorders (13 cases), advanced kidney failure (4 cases), and either cancer or concurrent respiratory illnesses (3 cases), as depicted in Fig. 1. Following these exclusions, the final cohort comprised 336 individuals. Within this group, medical professionals identified 165 cases of heart failure through comprehensive evaluation, including assessment of patient histories, clinical symptoms, NT-proBNP biomarker measurements, and echocardiographic results (Fig. 1). For analytical purposes, the heart failure patients were then categorized into three equal groups according to their VAP-1 levels. Table 1 presents comprehensive demographic and clinical characteristics of the study population. The average age of participants was 70.4 years (SD 11.6), with males constituting the majority (71.5%). Notably, individuals in the lowest VAP-1 tertile tended to be younger than other groups. Analysis revealed a direct relationship between VAP-1 concentrations and both NT-proBNP and LVDD in HF patients (P = 0.003), while an inverse correlation was observed with LVEF (P = 0.001). Over a median follow-up period of 30 months (IQR 17–35), MACE showed a non-significant trend toward increasing frequency with higher VAP-1 tertiles. Nevertheless, patients with elevated VAP-1 concentrations experienced significantly earlier occurrence of MACE (P < 0.001). The study also uncovered important connections between VAP-1 concentrations and coronary heart disease (CHD) in HF patients, demonstrating that higher sVAP-1 concentrations showed significant association with angina symptoms, while reduced concentrations indicated a lower risk of myocardial infarction. Additionally, individuals demonstrating heightened VAP-1 concentrations showed elevated Scr, BUN, and sodium values, along with a concurrent decrease in eGFR. while experiencing diminished estimated glomerular filtration rates. Table 1Baseline characteristics of patients with HFVariablesVAP-1 (ng/mL)P valueTotal (n = 165)Q1 (≤ 860)Q2 (860–1335)Q3 (≥ 1335)(n = 55)(n = 55)(n = 55)Gender (male), n (%)118 (71.5)34 (61.8)42 (76.4)42 (76.4)0.149Age (years)70.4 ± 11.666.2 ± 14.972.3 ± 9.372.7 ± 8.50.004BMI (Kg/㎡)24.4 ± 3.825.9 ± 3.723.6 ± 3.923.7 ± 3.50.002Af, n (%)76 (46.1)22 (40)23 (41.8)31 (56.4)0.169IS, n (%)23 (13.9)5 (9.1)10 (18.2)8 (14.5)0.383CHD, n (%)0.044non-CHD84 (50.9)27 (49.1)30 (54.5)27 (49.1)AP40 (24.2)9 (16.4)11 (20)20 (36.4)AMI41 (24.8)19 (34.5)14 (25.5)8 (14.5)HBP, n (%)103 (62.4)40 (72.7)31 (56.4)32 (58.2)0.152DM, n (%)57 (34.5)20 (36.4)18 (32.7)19 (34.5)0.923COPD, n (%)19 (11.5)5 (9.1)7 (12.7)7 (12.7)0.788Smoke, n (%)57 (34.5)19 (34.5)21 (38.2)17 (30.9)0.725Drink, n (%)25 (15.2)10 (18.2)8 (14.5)7 (12.7)0.719SBP (mmHg)132.8 ± 23.5137.3 ± 21.8127.1 ± 21.3133.9 ± 26.20.067DBP (mmHg)76.0 ± 13.677.8 ± 12.074.9 ± 13.575.4 ± 15.20.495Heart rate(beats per minute)82.6 ± 13.782.4 ± 14.983.2 ± 12.582.3 ± 13.80.923WBC (×109/L)7.3 ± 2.67.5 ± 2.87.4 ± 2.66.9 ± 2.40.454Neutrophi l(×109/L)5.5 ± 2.65.8 ± 2.75.8 ± 2.85.0 ± 2.20.244Lymphocyte (×109/L)1.3 ± 0.61.3 ± 0.61.3 ± 0.61.2 ± 0.40.699Monocyte (×109/L)0.5 ± 0.20.5 ± 0.20.5 ± 0.20.5 ± 0.20.884Hemoglobin (g/L)128.7 ± 18.4131.8 ± 18.3125.5 ± 17.7128.8 ± 19.10.202PLT (×1012/L)183.7 ± 62.1198.0 ± 66.0182.4 ± 58.9170.7 ± 59.40.068CRP (mg/L)6.2 ± 2.76.2 ± 3.25.6 ± 1.16.8 ± 3.00.06Scr (umol/L)92.7 ± 34.282.1 ± 29.994.1 ± 36.7101.9 ± 33.50.009Bun (mmol/L)7.1 ± 2.66.3 ± 2.47.4 ± 2.57.6 ± 2.70.017UA (umol/L)415.5 ± 142.8402.9 ± 133.7404.6 ± 148.6438.9 ± 145.30.331eGFR (ml/min)75.7 ± 30.490.2 ± 33.175.0 ± 26.361.8 ± 24.6< 0.001TG (mmol/L)1.1 (0.8, 1.5)1.2 (0.9, 1.8)1.0 (0.8, 1.4)1.0 (0.8, 1.3)0.051TC (mmol/L)3.7 ± 1.03.9 ± 1.13.7 ± 1.13.6 ± 0.90.409HDL (mmol/L)1.0 ± 0.31.1 ± 0.31.1 ± 0.31.0 ± 0.30.418VLDL (mmol/L)0.4 (0.3, 0.6)0.4 (0.3, 0.6)0.4 (0.3, 0.6)0.4 (0.3, 0.6)0.867LDL (mmol/L)2.3 ± 1.02.5 ± 1.12.3 ± 1.02.1 ± 0.80.183FBG (mmol/L)6.5 ± 2.26.3 ± 1.86.6 ± 2.36.6 ± 2.50.815HbA1c (%)6.3 ± 0.96.1 ± 0.96.4 ± 1.06.4 ± 0.90.241ALT (U/L)24.0 (13.0, 35.0)25.0 (12.0, 36.0)24.0 (14.5, 34.0)22.0 (12.0, 31.0)0.844AST (U/L)25.0 (18.0, 38.4)25.0 (18.5, 38.4)27.0 (19.0, 38.4)24.0 (16.0, 34.0)0.383TBIL (mmol/L)13.9 (9.6, 18.8)13.5 (10.2, 17.2)12.9 (9.2, 18.2)14.1 (9.6, 20.0)0.795IBIL (mmol/L)5.6 (4.3, 7.4)5.8 (4.4, 7.2)5.5 (4.0, 7.0)6.3 (4.4, 8.1)0.216ALB (g/L)37.2 ± 4.537.5 ± 4.737.1 ± 4.837.1 ± 4.10.883Sodium (mmol/L)140.3 ± 3.9140.6 ± 3.3141.1 ± 4.1139.2 ± 4.20.033Potassium (mmol/L)3.9 ± 0.43.8 ± 0.44.0 ± 0.53.9 ± 0.40.134Chlorine (mmol/L)103.4 ± 4.3103.5 ± 3.8103.4 ± 3.7103.4 ± 5.40.993CK (U/L)91.0 (59.0, 247.0)94.0 (64.0, 318.8)87.0 (56.5, 197.5)101.0 (60.0, 178.0)0.404CTnT (pg/mL)30.0 (12.5, 165.0)47.0 (10.0, 1121.7)28.0 (13.0, 137.5)27.0 (14.5, 62.5)0.563NT-proBNP (pg/mL)3195.9 (1464.0, 7272.0)2522.0 (1251.0, 3716.0)3195.9 (1421.5, 9281.0)4840.0 (2211.5, 13133.5)< 0.001D dimer (ug/mL)0.7 (0.3, 1.4)0.6 (0.3, 1.1)0.7 (0.3, 1.7)0.7 (0.4, 1.3)0.79LVEF (%)43.5 ± 13.649.2 ± 13.040.7 ± 13.140.6 ± 13.3< 0.001LAD (mm)49.2 ± 8.248.2 ± 7.748.5 ± 8.650.9 ± 8.20.159LVDD (mm)56.6 ± 9.653.3 ± 7.458.2 ± 10.558.3 ± 9.90.008MACE, n (%)64 (38.8)17 (30.9)20 (36.4)27 (49.1)0.133Time of MACE (weeks)14.0 (8.0, 31.0)30.0 (14.0, 35.0)14.0 (9.0, 30.5)11.0 (5.0, 14.0)< 0.001Percentage calculated from the total population; some factors total < 100% due to missing dataAbbreviations: HF heart failure, VAP-1 Vascular adhesion protein-1, IS Ischemic stroke, CHD coronary heart disease, non-CHD patients without coronary heart disease, AP angor pectoris, AMI acute myocardial infarction, BMI Body Mass Index, Af atrial fibrillation, HBP high blood pressure, DM diabetes mellitus, COPD chronic obstructive pulmonary disease, SBP systolic blood pressure, DBP diastolic blood pressure, WBC white blood cell, PLT platelet, CRP C-reactive protein, Scr serum creatinine, Bun blood urea nitrogen, UA serum uric acid, eGFR estimated glomerular filtrationrate, TG triglyceride, TC total cholesterol, HDL high-density lipoprotein cholesterol, VLDL very low density lipoprotein cholesterol, LDL low density lipoprotein cholesterol, FBG fasting blood-glucose, HbA1c Glycated hemoglobin A1c, ALT serum glutamic pyruvic transaminase, AST serum glutamic oxalacetic transaminase, TBil total bilirubin, IBil indirect bilirubin, ALB serum albumin, CK creatine kinase, CTnT cardiac troponin T, NT-proBNP N terminal brain natriuretic peptide precursor, LVEF left ventricular ejection fraction, LAD left atrial diameter, LVDD left ventricular end-diastolic dimension, MACE major adverse cardiovascular events Table 1Baseline characteristics of patients with HFVariablesVAP-1 (ng/mL)P valueTotal (n = 165)Q1 (≤ 860)Q2 (860–1335)Q3 (≥ 1335)(n = 55)(n = 55)(n = 55)Gender (male), n (%)118 (71.5)34 (61.8)42 (76.4)42 (76.4)0.149Age (years)70.4 ± 11.666.2 ± 14.972.3 ± 9.372.7 ± 8.50.004BMI (Kg/㎡)24.4 ± 3.825.9 ± 3.723.6 ± 3.923.7 ± 3.50.002Af, n (%)76 (46.1)22 (40)23 (41.8)31 (56.4)0.169IS, n (%)23 (13.9)5 (9.1)10 (18.2)8 (14.5)0.383CHD, n (%)0.044non-CHD84 (50.9)27 (49.1)30 (54.5)27 (49.1)AP40 (24.2)9 (16.4)11 (20)20 (36.4)AMI41 (24.8)19 (34.5)14 (25.5)8 (14.5)HBP, n (%)103 (62.4)40 (72.7)31 (56.4)32 (58.2)0.152DM, n (%)57 (34.5)20 (36.4)18 (32.7)19 (34.5)0.923COPD, n (%)19 (11.5)5 (9.1)7 (12.7)7 (12.7)0.788Smoke, n (%)57 (34.5)19 (34.5)21 (38.2)17 (30.9)0.725Drink, n (%)25 (15.2)10 (18.2)8 (14.5)7 (12.7)0.719SBP (mmHg)132.8 ± 23.5137.3 ± 21.8127.1 ± 21.3133.9 ± 26.20.067DBP (mmHg)76.0 ± 13.677.8 ± 12.074.9 ± 13.575.4 ± 15.20.495Heart rate(beats per minute)82.6 ± 13.782.4 ± 14.983.2 ± 12.582.3 ± 13.80.923WBC (×109/L)7.3 ± 2.67.5 ± 2.87.4 ± 2.66.9 ± 2.40.454Neutrophi l(×109/L)5.5 ± 2.65.8 ± 2.75.8 ± 2.85.0 ± 2.20.244Lymphocyte (×109/L)1.3 ± 0.61.3 ± 0.61.3 ± 0.61.2 ± 0.40.699Monocyte (×109/L)0.5 ± 0.20.5 ± 0.20.5 ± 0.20.5 ± 0.20.884Hemoglobin (g/L)128.7 ± 18.4131.8 ± 18.3125.5 ± 17.7128.8 ± 19.10.202PLT (×1012/L)183.7 ± 62.1198.0 ± 66.0182.4 ± 58.9170.7 ± 59.40.068CRP (mg/L)6.2 ± 2.76.2 ± 3.25.6 ± 1.16.8 ± 3.00.06Scr (umol/L)92.7 ± 34.282.1 ± 29.994.1 ± 36.7101.9 ± 33.50.009Bun (mmol/L)7.1 ± 2.66.3 ± 2.47.4 ± 2.57.6 ± 2.70.017UA (umol/L)415.5 ± 142.8402.9 ± 133.7404.6 ± 148.6438.9 ± 145.30.331eGFR (ml/min)75.7 ± 30.490.2 ± 33.175.0 ± 26.361.8 ± 24.6< 0.001TG (mmol/L)1.1 (0.8, 1.5)1.2 (0.9, 1.8)1.0 (0.8, 1.4)1.0 (0.8, 1.3)0.051TC (mmol/L)3.7 ± 1.03.9 ± 1.13.7 ± 1.13.6 ± 0.90.409HDL (mmol/L)1.0 ± 0.31.1 ± 0.31.1 ± 0.31.0 ± 0.30.418VLDL (mmol/L)0.4 (0.3, 0.6)0.4 (0.3, 0.6)0.4 (0.3, 0.6)0.4 (0.3, 0.6)0.867LDL (mmol/L)2.3 ± 1.02.5 ± 1.12.3 ± 1.02.1 ± 0.80.183FBG (mmol/L)6.5 ± 2.26.3 ± 1.86.6 ± 2.36.6 ± 2.50.815HbA1c (%)6.3 ± 0.96.1 ± 0.96.4 ± 1.06.4 ± 0.90.241ALT (U/L)24.0 (13.0, 35.0)25.0 (12.0, 36.0)24.0 (14.5, 34.0)22.0 (12.0, 31.0)0.844AST (U/L)25.0 (18.0, 38.4)25.0 (18.5, 38.4)27.0 (19.0, 38.4)24.0 (16.0, 34.0)0.383TBIL (mmol/L)13.9 (9.6, 18.8)13.5 (10.2, 17.2)12.9 (9.2, 18.2)14.1 (9.6, 20.0)0.795IBIL (mmol/L)5.6 (4.3, 7.4)5.8 (4.4, 7.2)5.5 (4.0, 7.0)6.3 (4.4, 8.1)0.216ALB (g/L)37.2 ± 4.537.5 ± 4.737.1 ± 4.837.1 ± 4.10.883Sodium (mmol/L)140.3 ± 3.9140.6 ± 3.3141.1 ± 4.1139.2 ± 4.20.033Potassium (mmol/L)3.9 ± 0.43.8 ± 0.44.0 ± 0.53.9 ± 0.40.134Chlorine (mmol/L)103.4 ± 4.3103.5 ± 3.8103.4 ± 3.7103.4 ± 5.40.993CK (U/L)91.0 (59.0, 247.0)94.0 (64.0, 318.8)87.0 (56.5, 197.5)101.0 (60.0, 178.0)0.404CTnT (pg/mL)30.0 (12.5, 165.0)47.0 (10.0, 1121.7)28.0 (13.0, 137.5)27.0 (14.5, 62.5)0.563NT-proBNP (pg/mL)3195.9 (1464.0, 7272.0)2522.0 (1251.0, 3716.0)3195.9 (1421.5, 9281.0)4840.0 (2211.5, 13133.5)< 0.001D dimer (ug/mL)0.7 (0.3, 1.4)0.6 (0.3, 1.1)0.7 (0.3, 1.7)0.7 (0.4, 1.3)0.79LVEF (%)43.5 ± 13.649.2 ± 13.040.7 ± 13.140.6 ± 13.3< 0.001LAD (mm)49.2 ± 8.248.2 ± 7.748.5 ± 8.650.9 ± 8.20.159LVDD (mm)56.6 ± 9.653.3 ± 7.458.2 ± 10.558.3 ± 9.90.008MACE, n (%)64 (38.8)17 (30.9)20 (36.4)27 (49.1)0.133Time of MACE (weeks)14.0 (8.0, 31.0)30.0 (14.0, 35.0)14.0 (9.0, 30.5)11.0 (5.0, 14.0)< 0.001Percentage calculated from the total population; some factors total < 100% due to missing dataAbbreviations: HF heart failure, VAP-1 Vascular adhesion protein-1, IS Ischemic stroke, CHD coronary heart disease, non-CHD patients without coronary heart disease, AP angor pectoris, AMI acute myocardial infarction, BMI Body Mass Index, Af atrial fibrillation, HBP high blood pressure, DM diabetes mellitus, COPD chronic obstructive pulmonary disease, SBP systolic blood pressure, DBP diastolic blood pressure, WBC white blood cell, PLT platelet, CRP C-reactive protein, Scr serum creatinine, Bun blood urea nitrogen, UA serum uric acid, eGFR estimated glomerular filtrationrate, TG triglyceride, TC total cholesterol, HDL high-density lipoprotein cholesterol, VLDL very low density lipoprotein cholesterol, LDL low density lipoprotein cholesterol, FBG fasting blood-glucose, HbA1c Glycated hemoglobin A1c, ALT serum glutamic pyruvic transaminase, AST serum glutamic oxalacetic transaminase, TBil total bilirubin, IBil indirect bilirubin, ALB serum albumin, CK creatine kinase, CTnT cardiac troponin T, NT-proBNP N terminal brain natriuretic peptide precursor, LVEF left ventricular ejection fraction, LAD left atrial diameter, LVDD left ventricular end-diastolic dimension, MACE major adverse cardiovascular events Baseline characteristics of patients with HF Percentage calculated from the total population; some factors total < 100% due to missing data Abbreviations: HF heart failure, VAP-1 Vascular adhesion protein-1, IS Ischemic stroke, CHD coronary heart disease, non-CHD patients without coronary heart disease, AP angor pectoris, AMI acute myocardial infarction, BMI Body Mass Index, Af atrial fibrillation, HBP high blood pressure, DM diabetes mellitus, COPD chronic obstructive pulmonary disease, SBP systolic blood pressure, DBP diastolic blood pressure, WBC white blood cell, PLT platelet, CRP C-reactive protein, Scr serum creatinine, Bun blood urea nitrogen, UA serum uric acid, eGFR estimated glomerular filtrationrate, TG triglyceride, TC total cholesterol, HDL high-density lipoprotein cholesterol, VLDL very low density lipoprotein cholesterol, LDL low density lipoprotein cholesterol, FBG fasting blood-glucose, HbA1c Glycated hemoglobin A1c, ALT serum glutamic pyruvic transaminase, AST serum glutamic oxalacetic transaminase, TBil total bilirubin, IBil indirect bilirubin, ALB serum albumin, CK creatine kinase, CTnT cardiac troponin T, NT-proBNP N terminal brain natriuretic peptide precursor, LVEF left ventricular ejection fraction, LAD left atrial diameter, LVDD left ventricular end-diastolic dimension, MACE major adverse cardiovascular events Serum VAP-1 levels and MACE in HF patients The study employed both univariate and multivariate statistical approaches to assess clinical, demographic, biochemical, and imaging characteristics in heart failure patients, aiming to determine independent predictors associated with MACE (Tables 2 and 3). Preliminary univariate examination revealed statistically meaningful correlations between MACE occurrence and numerous factors, notably VAP-1 concentrations (P < 0.001), alongside other variables like age, BMI, Af, CHD, smoking history, various blood cell counts (white blood cell, neutrophils, lymphocytes, monocytes), hemoglobin, platelets, kidney function indicators (Scr, BUN, eGFR), lipid measurements (TG, TC, LDL-C), liver enzyme activity (AST), bilirubin components (total and indirect), serum albumin, cardiac markers (CK, CTnT, NT-proBNP), clotting factors (D-dimer), and cardiac ultrasound measurements (LAD, LVDD), as presented in Table 2. Following this initial analysis, We applied a multivariate Cox regression model to evaluate VAP-1’s predictive capacity for MACE risk in the HF population. As illustrated in Table 3, the unadjusted (crude) model revealed a significant, dose-dependent relationship between increasing levels of VAP-1 and the risk of MACE (Q2 vs. Q1: hazard ratio [HR] = 1.59, 95% confidence interval [CI] = 0.83–3.05; Q3 vs. Q1: HR = 2.6, 95% CI = 1.38–4.89). These findings persisted through various statistical adjustments (Q2 versus Q1: HR = 1.7, 95% CI = 0.71–4.12; Q3 versus Q1: HR = 2.85, 95% CI = 1.1–7.36), with all models showing a statistically meaningful linear trend (P = 0.029). Nevertheless, supplementary analyses conducted on the overall population (Supplementary Tables 5–7) failed to establish a statistically significant link​ connecting VAP-1 levels to the incidence of MACE. The survival probability analysis using Kaplan-Meier methodology corroborated these observations, demonstrating progressively higher MACE rates corresponding to elevated VAP-1 concentrations over a 35-week observation period in HF patients (Q3 > Q2 > Q1; P = 0.0085; Fig. 2). Consistent with this, a positive relationship was observed between rising VAP-1 measurements and the frequency of MACE in HF patients, as determined by curve-fitting (P = 0.438; Fig. 3). Furthermore, to investigate potential non-linear relationships, a segmented regression approach combining multivariate analysis with curve fitting was employed to identify potential thresholds in the data. The results demonstrated a strong positive association with statistical significance between major adverse cardiovascular events and vascular adhesion protein-1 concentrations surpassing 1355 ng/mL. Conversely, this relationship lost statistical significance when VAP-1 measurements fell below this critical threshold, as detailed in Table 4. Table 2Univariate Cox regression analysis of risk factors associated with MACE in patients with HFVariablesHR (95%CI)P valueVAP-1 (ng/mL)1.0008 (1.0004,1.0012)< 0.001Gender (male)0.89 (0.52,1.52)0.662Age (years)1.06 (1.03,1.08)< 0.001BMI (Kg/㎡)0.88 (0.81,0.94)< 0.001Af (no)2.1 (1.26,3.5)0.005IS (no)1.36 (0.68,2.69)0.383CHDAP1.28 (0.73,2.24)0.394AMI0.14 (0.06,0.35)< 0.001HBP (no)1.14 (0.67,1.93)0.628DM (no)0.93 (0.55,1.56)0.77COPD (no)0.95 (0.38,2.39)0.92Smoke (no)0.54 (0.31,0.95)0.032Drink (no)0.43 (0.18,1.01)0.052SBP (mmHg)0.9914 (0.9802,1.0026)0.133DBP (mmHg)0.99 (0.97,1.01)0.232heart rate (beats per minute)0.9984 (0.9791,1.018)0.871WBC (×109/L)0.86 (0.78,0.96)0.005Neutrophil (×109/L)0.87 (0.78,0.97)0.009Lymphocyte (×109/L)0.57 (0.35,0.93)0.025Monocyte (×109/L)0.41 (0.13,1.33)0.136Hemoglobin (g/L)0.98 (0.96,0.99)< 0.001PLT (×1012/L)0.9954 (0.9912,0.9996)0.033CRP (mg/L)1.03 (0.95,1.12)0.457Scr (umol/L)1.0083 (1.0015,1.0151)0.016Bun (mmol/L)1.14 (1.04,1.24)0.005UA (umol/L)1.0033 (1.0016,1.0051)< 0.001eGFR (ml/min)0.98 (0.97,0.99)< 0.001TG (mmol/L)0.62 (0.39,0.97)0.038TC (mmol/L)0.74 (0.57,0.96)0.022HDL (mmol/L)0.72 (0.27,1.91)0.511VLDL (mmol/L)1.51 (0.6,3.77)0.379LDL (mmol/L)0.7 (0.53,0.92)0.012FBG (mmol/L)0.89 (0.78,1.02)0.091HbA1c (%)0.92 (0.71,1.2)0.544ALT (U/L)0.9921 (0.9773,1.0071)0.299AST (U/L)0.98 (0.97,0.99)0.003TBIL (mmol/L)1.03 (1,1.06)0.039IBIL (mmol/L)1.17 (1.09,1.25)< 0.001ALB (g/L)0.88 (0.83,0.94)< 0.001Sodium (mmol/L)0.99 (0.93,1.05)0.722Potassium (mmol/L)0.94 (0.52,1.73)0.849Chlorine (mmol/L)1.0039 (0.9461,1.0653)0.897CK (U/L)0.9979 (0.9965,0.9993)0.004CTnT (pg/mL)0.9986 (0.9976,0.9995)0.004NT-proBNP (pg/mL)1.0001 (1,1.0001)< 0.001D dimer (ug/mL)1.2 (1.08,1.34)< 0.001LVEF (%)0.98 (0.96,1)0.057LAD (mm)1.05 (1.03,1.08)< 0.001LVDD (mm)1.03 (1.01,1.06)0.015Abbreviations: HF heart failure, VAP-1 Vascular adhesion protein-1, IS Ischemic stroke, CHD coronary heart disease, non-CHD patients without coronary heart disease, AP angor pectoris, AMI acute myocardial infarction, BMI Body Mass Index, Af atrial fibrillation, HBP high blood pressure, DM diabetes mellitus, COPD chronic obstructive pulmonary disease, SBP systolic blood pressure, DBP diastolic blood pressure, WBC white blood cell, PLT platelet, CRP C-reactive protein, Scr serum creatinine, Bun blood urea nitrogen, UA serum uric acid, eGFR estimated glomerular filtrationrate, TG triglyceride, TC total cholesterol, HDL high-density lipoprotein cholesterol, VLDL very low density lipoprotein cholesterol, LDL low density lipoprotein cholesterol, FBG fasting blood-glucose, HbA1c Glycated hemoglobin A1c, ALT serum glutamic pyruvic transaminase, AST serum glutamic oxalacetic transaminase, TBil total bilirubin, IBil indirect bilirubin, ALB serum albumin, CK creatine kinase, CTnT cardiac troponin T, NT-proBNP N terminal brain natriuretic peptide precursor, LVEF left ventricular ejection fraction, LAD left atrial diameter, LVDD left ventricular end-diastolic dimension Table 2Univariate Cox regression analysis of risk factors associated with MACE in patients with HFVariablesHR (95%CI)P valueVAP-1 (ng/mL)1.0008 (1.0004,1.0012)< 0.001Gender (male)0.89 (0.52,1.52)0.662Age (years)1.06 (1.03,1.08)< 0.001BMI (Kg/㎡)0.88 (0.81,0.94)< 0.001Af (no)2.1 (1.26,3.5)0.005IS (no)1.36 (0.68,2.69)0.383CHDAP1.28 (0.73,2.24)0.394AMI0.14 (0.06,0.35)< 0.001HBP (no)1.14 (0.67,1.93)0.628DM (no)0.93 (0.55,1.56)0.77COPD (no)0.95 (0.38,2.39)0.92Smoke (no)0.54 (0.31,0.95)0.032Drink (no)0.43 (0.18,1.01)0.052SBP (mmHg)0.9914 (0.9802,1.0026)0.133DBP (mmHg)0.99 (0.97,1.01)0.232heart rate (beats per minute)0.9984 (0.9791,1.018)0.871WBC (×109/L)0.86 (0.78,0.96)0.005Neutrophil (×109/L)0.87 (0.78,0.97)0.009Lymphocyte (×109/L)0.57 (0.35,0.93)0.025Monocyte (×109/L)0.41 (0.13,1.33)0.136Hemoglobin (g/L)0.98 (0.96,0.99)< 0.001PLT (×1012/L)0.9954 (0.9912,0.9996)0.033CRP (mg/L)1.03 (0.95,1.12)0.457Scr (umol/L)1.0083 (1.0015,1.0151)0.016Bun (mmol/L)1.14 (1.04,1.24)0.005UA (umol/L)1.0033 (1.0016,1.0051)< 0.001eGFR (ml/min)0.98 (0.97,0.99)< 0.001TG (mmol/L)0.62 (0.39,0.97)0.038TC (mmol/L)0.74 (0.57,0.96)0.022HDL (mmol/L)0.72 (0.27,1.91)0.511VLDL (mmol/L)1.51 (0.6,3.77)0.379LDL (mmol/L)0.7 (0.53,0.92)0.012FBG (mmol/L)0.89 (0.78,1.02)0.091HbA1c (%)0.92 (0.71,1.2)0.544ALT (U/L)0.9921 (0.9773,1.0071)0.299AST (U/L)0.98 (0.97,0.99)0.003TBIL (mmol/L)1.03 (1,1.06)0.039IBIL (mmol/L)1.17 (1.09,1.25)< 0.001ALB (g/L)0.88 (0.83,0.94)< 0.001Sodium (mmol/L)0.99 (0.93,1.05)0.722Potassium (mmol/L)0.94 (0.52,1.73)0.849Chlorine (mmol/L)1.0039 (0.9461,1.0653)0.897CK (U/L)0.9979 (0.9965,0.9993)0.004CTnT (pg/mL)0.9986 (0.9976,0.9995)0.004NT-proBNP (pg/mL)1.0001 (1,1.0001)< 0.001D dimer (ug/mL)1.2 (1.08,1.34)< 0.001LVEF (%)0.98 (0.96,1)0.057LAD (mm)1.05 (1.03,1.08)< 0.001LVDD (mm)1.03 (1.01,1.06)0.015Abbreviations: HF heart failure, VAP-1 Vascular adhesion protein-1, IS Ischemic stroke, CHD coronary heart disease, non-CHD patients without coronary heart disease, AP angor pectoris, AMI acute myocardial infarction, BMI Body Mass Index, Af atrial fibrillation, HBP high blood pressure, DM diabetes mellitus, COPD chronic obstructive pulmonary disease, SBP systolic blood pressure, DBP diastolic blood pressure, WBC white blood cell, PLT platelet, CRP C-reactive protein, Scr serum creatinine, Bun blood urea nitrogen, UA serum uric acid, eGFR estimated glomerular filtrationrate, TG triglyceride, TC total cholesterol, HDL high-density lipoprotein cholesterol, VLDL very low density lipoprotein cholesterol, LDL low density lipoprotein cholesterol, FBG fasting blood-glucose, HbA1c Glycated hemoglobin A1c, ALT serum glutamic pyruvic transaminase, AST serum glutamic oxalacetic transaminase, TBil total bilirubin, IBil indirect bilirubin, ALB serum albumin, CK creatine kinase, CTnT cardiac troponin T, NT-proBNP N terminal brain natriuretic peptide precursor, LVEF left ventricular ejection fraction, LAD left atrial diameter, LVDD left ventricular end-diastolic dimension Univariate Cox regression analysis of risk factors associated with MACE in patients with HF Abbreviations: HF heart failure, VAP-1 Vascular adhesion protein-1, IS Ischemic stroke, CHD coronary heart disease, non-CHD patients without coronary heart disease, AP angor pectoris, AMI acute myocardial infarction, BMI Body Mass Index, Af atrial fibrillation, HBP high blood pressure, DM diabetes mellitus, COPD chronic obstructive pulmonary disease, SBP systolic blood pressure, DBP diastolic blood pressure, WBC white blood cell, PLT platelet, CRP C-reactive protein, Scr serum creatinine, Bun blood urea nitrogen, UA serum uric acid, eGFR estimated glomerular filtrationrate, TG triglyceride, TC total cholesterol, HDL high-density lipoprotein cholesterol, VLDL very low density lipoprotein cholesterol, LDL low density lipoprotein cholesterol, FBG fasting blood-glucose, HbA1c Glycated hemoglobin A1c, ALT serum glutamic pyruvic transaminase, AST serum glutamic oxalacetic transaminase, TBil total bilirubin, IBil indirect bilirubin, ALB serum albumin, CK creatine kinase, CTnT cardiac troponin T, NT-proBNP N terminal brain natriuretic peptide precursor, LVEF left ventricular ejection fraction, LAD left atrial diameter, LVDD left ventricular end-diastolic dimension Table 3Multivariate Cox regression analysis of risk factors associated with MACE in patients with HFVariableNon-adjusted ModelP valueModel IP valueModel IIP valueModel IIIP valueHR(95%CI)HR(95%CI)HR(95%CI)HR(95%CI) VAP-1(ng/mL) Q1(≤ 860)1(Ref)1(Ref)1(Ref)1(Ref)Q2(860–1335)1.59 (0.83 ~ 3.05)0.1651.27 (0.64 ~ 2.51)0.4911.67 (0.72 ~ 3.86)0.231.7 (0.71 ~ 4.12)0.236Q3(≥ 1335)2.6 (1.38 ~ 4.89)0.0032.12 (1.11 ~ 4.04)0.0232.78 (1.17 ~ 6.6)0.0212.85 (1.1 ~ 7.36)0.031 Trend test 1.61 (1.18 ~ 2.21)0.0031.47 (1.06 ~ 2.04)0.021.67 (1.08 ~ 2.56)0.021.69 (1.05 ~ 2.69)0.029data presented are HR and 95% CIsNon-adjusted Model: We did not adjust any covariantsModel I: Adjusted for Gender, AgeModel II: Adjusted for the variables in Model I plus Af, CHD, Smoke, Neutrophil, Lymphocyte, hemoglobin, PLT, Scr, Bun, UA, eGFR, TG, TC, LDL, TBIL, IBIL, ALB, CK, CTnT, NTproBNP, D dimer, LAD, LVDDModel III: Adjusted for the variables in Model II plus HBP, IS, DM, COPD, Drink, SBP, DBP, heart rate, HDL, FBG, LVEF. In each case, the model is not adjusted for the variable itselfAbbreviations: MACE major adverse cardiovascular events, HF heart failure, VAP-1 Vascular adhesion protein-1, Af atrial fibrillation, CHD coronary heart disease, WBC white blood cell, PLT platelet, Scr serum creatinine, Bun blood urea nitrogen, UA serum uric acid, eGFR esti mated glomerularfiltrationrate, TG triglyceride, TC total cholesterol, LDL low density lipoprotein cholesterol, AST serum glutamic oxalacetic transaminase, TBil total bilirubin, IBil indirect bilirubin, ALB serum albumin, CK creatine kinase, CTnT cardiac troponin T, NT-proBNP N terminal brain natriuretic peptide precursor, LAD left atrial diameter, LVDD left ventricular end-diastolic dimension, HBP high blood pressure, IS Ischemic stroke, DM diabetes mellitus, COPD chronic obstructive pulmonary disease, SBP systolic blood pressure, DBP diastolic blood pressure, ALT serum glutamic pyruvic transaminase, HDL high-density lipoprotein cholesterol, FBG fasting blood-glucose, LVEF left ventricular ejection fraction Table 3Multivariate Cox regression analysis of risk factors associated with MACE in patients with HFVariableNon-adjusted ModelP valueModel IP valueModel IIP valueModel IIIP valueHR(95%CI)HR(95%CI)HR(95%CI)HR(95%CI) VAP-1(ng/mL) Q1(≤ 860)1(Ref)1(Ref)1(Ref)1(Ref)Q2(860–1335)1.59 (0.83 ~ 3.05)0.1651.27 (0.64 ~ 2.51)0.4911.67 (0.72 ~ 3.86)0.231.7 (0.71 ~ 4.12)0.236Q3(≥ 1335)2.6 (1.38 ~ 4.89)0.0032.12 (1.11 ~ 4.04)0.0232.78 (1.17 ~ 6.6)0.0212.85 (1.1 ~ 7.36)0.031 Trend test 1.61 (1.18 ~ 2.21)0.0031.47 (1.06 ~ 2.04)0.021.67 (1.08 ~ 2.56)0.021.69 (1.05 ~ 2.69)0.029data presented are HR and 95% CIsNon-adjusted Model: We did not adjust any covariantsModel I: Adjusted for Gender, AgeModel II: Adjusted for the variables in Model I plus Af, CHD, Smoke, Neutrophil, Lymphocyte, hemoglobin, PLT, Scr, Bun, UA, eGFR, TG, TC, LDL, TBIL, IBIL, ALB, CK, CTnT, NTproBNP, D dimer, LAD, LVDDModel III: Adjusted for the variables in Model II plus HBP, IS, DM, COPD, Drink, SBP, DBP, heart rate, HDL, FBG, LVEF. In each case, the model is not adjusted for the variable itselfAbbreviations: MACE major adverse cardiovascular events, HF heart failure, VAP-1 Vascular adhesion protein-1, Af atrial fibrillation, CHD coronary heart disease, WBC white blood cell, PLT platelet, Scr serum creatinine, Bun blood urea nitrogen, UA serum uric acid, eGFR esti mated glomerularfiltrationrate, TG triglyceride, TC total cholesterol, LDL low density lipoprotein cholesterol, AST serum glutamic oxalacetic transaminase, TBil total bilirubin, IBil indirect bilirubin, ALB serum albumin, CK creatine kinase, CTnT cardiac troponin T, NT-proBNP N terminal brain natriuretic peptide precursor, LAD left atrial diameter, LVDD left ventricular end-diastolic dimension, HBP high blood pressure, IS Ischemic stroke, DM diabetes mellitus, COPD chronic obstructive pulmonary disease, SBP systolic blood pressure, DBP diastolic blood pressure, ALT serum glutamic pyruvic transaminase, HDL high-density lipoprotein cholesterol, FBG fasting blood-glucose, LVEF left ventricular ejection fraction Multivariate Cox regression analysis of risk factors associated with MACE in patients with HF data presented are HR and 95% CIs Non-adjusted Model: We did not adjust any covariants Model I: Adjusted for Gender, Age Model II: Adjusted for the variables in Model I plus Af, CHD, Smoke, Neutrophil, Lymphocyte, hemoglobin, PLT, Scr, Bun, UA, eGFR, TG, TC, LDL, TBIL, IBIL, ALB, CK, CTnT, NTproBNP, D dimer, LAD, LVDD Model III: Adjusted for the variables in Model II plus HBP, IS, DM, COPD, Drink, SBP, DBP, heart rate, HDL, FBG, LVEF. In each case, the model is not adjusted for the variable itself Abbreviations: MACE major adverse cardiovascular events, HF heart failure, VAP-1 Vascular adhesion protein-1, Af atrial fibrillation, CHD coronary heart disease, WBC white blood cell, PLT platelet, Scr serum creatinine, Bun blood urea nitrogen, UA serum uric acid, eGFR esti mated glomerularfiltrationrate, TG triglyceride, TC total cholesterol, LDL low density lipoprotein cholesterol, AST serum glutamic oxalacetic transaminase, TBil total bilirubin, IBil indirect bilirubin, ALB serum albumin, CK creatine kinase, CTnT cardiac troponin T, NT-proBNP N terminal brain natriuretic peptide precursor, LAD left atrial diameter, LVDD left ventricular end-diastolic dimension, HBP high blood pressure, IS Ischemic stroke, DM diabetes mellitus, COPD chronic obstructive pulmonary disease, SBP systolic blood pressure, DBP diastolic blood pressure, ALT serum glutamic pyruvic transaminase, HDL high-density lipoprotein cholesterol, FBG fasting blood-glucose, LVEF left ventricular ejection fraction Fig. 2Kaplan-Meier survival curves for MACE of patients with HF. Abbreviations: VAP-1 = Vascular adhesion protein-1; MACE = major adverse cardiovascular events; HF = heart failure Kaplan-Meier survival curves for MACE of patients with HF. Abbreviations: VAP-1 = Vascular adhesion protein-1; MACE = major adverse cardiovascular events; HF = heart failure Fig. 3Relationship between VAP-1 and MACE in patients with HF. Adjusted for Gender, Age, Af, CHD, Smoke, Neutrophil, Lymphocyte, hemoglobin, PLT, Scr, Bun, UA, eGFR, TG, TC, LDL, TBIL, IBIL, ALB, CK, CTnT, NTproBNP, D dimer, LAD, LVDD, HBP, IS, DM, COPD, Drink, SBP, DBP, heart rate, HDL, FBG, LVEF. Abbreviations: MACE = major adverse cardiovascular events; HF = heart failure; VAP-1 = Vascular adhesion protein-1; Af = atrial fibrillation; CHD = coronary heart disease; PLT = platelet; Scr = serum creatinine; Bun = blood urea nitrogen; UA = serum uric acid; eGFR = esti mated glomerularfiltrationrate; TG = triglyceride; TC = total cholesterol; LDL = low density lipoprotein cholesterol; TBil = total bilirubin; IBil = indirect bilirubin; ALB = serum albumin; CK = creatine kinase; CTnT = cardiac troponin T; NT-proBNP = N terminal brain natriuretic peptide precursor; LAD = left atrial diameter; LVDD = left ventricular end-diastolic dimension; HBP = high blood pressure; IS = Ischemic stroke; DM= diabetes mellitus; COPD = chronic obstructive pulmonary disease; SBP = systolic blood pressure; DBP = diastolic blood pressure; HDL = high-density lipoprotein cholesterol; FBG = fasting blood-glucose; LVEF = left ventricular ejection fraction Relationship between VAP-1 and MACE in patients with HF. Adjusted for Gender, Age, Af, CHD, Smoke, Neutrophil, Lymphocyte, hemoglobin, PLT, Scr, Bun, UA, eGFR, TG, TC, LDL, TBIL, IBIL, ALB, CK, CTnT, NTproBNP, D dimer, LAD, LVDD, HBP, IS, DM, COPD, Drink, SBP, DBP, heart rate, HDL, FBG, LVEF. Abbreviations: MACE = major adverse cardiovascular events; HF = heart failure; VAP-1 = Vascular adhesion protein-1; Af = atrial fibrillation; CHD = coronary heart disease; PLT = platelet; Scr = serum creatinine; Bun = blood urea nitrogen; UA = serum uric acid; eGFR = esti mated glomerularfiltrationrate; TG = triglyceride; TC = total cholesterol; LDL = low density lipoprotein cholesterol; TBil = total bilirubin; IBil = indirect bilirubin; ALB = serum albumin; CK = creatine kinase; CTnT = cardiac troponin T; NT-proBNP = N terminal brain natriuretic peptide precursor; LAD = left atrial diameter; LVDD = left ventricular end-diastolic dimension; HBP = high blood pressure; IS = Ischemic stroke; DM= diabetes mellitus; COPD = chronic obstructive pulmonary disease; SBP = systolic blood pressure; DBP = diastolic blood pressure; HDL = high-density lipoprotein cholesterol; FBG = fasting blood-glucose; LVEF = left ventricular ejection fraction Table 4Treshold effect analysis of VAP-1 on MACE in patients with HFVAP-1(ng/mL)HR95% CIP value<13350.99930.9967–1.00190.5901≥ 13351.0631.06–1.066< 0.001Adjusted for Gender, Age, Af, CHD, Smoke, Neutrophil, Lymphocyte, hemoglobin, PLT, Scr, Bun, UA, eGFR, TG, TC, LDL, TBIL, IBIL, ALB, CK, CTnT, NTproBNP, D dimer, LAD, LVDD, HBP, IS, DM, COPD, Drink, SBP, DBP, heart rate, HDL, FBG, LVEF. Abbreviations: MACE major adverse cardiovascular events, HF heart failure, VAP-1 Vascular adhesion protein-1, Af atrial fibrillation, CHD coronary heart disease, Hb hemoglobin, PLT platelet, Scr serum creatinine, Bun blood urea nitrogen, UA serum uric acid, eGFR esti mated glomerularfiltrationrate, TG triglyceride, TC total cholesterol, LDL low density lipoprotein cholesterol, TBil total bilirubin, IBil indirect bilirubin, ALB serum albumin, CK creatine kinase, CTnT cardiac troponin T, NT-proBNP N terminal brain natriuretic peptide precursor, LAD left atrial diameter, LVDD left ventricular end-diastolic dimension, HBP high blood pressure, IS Ischemic stroke, DM diabetes mellitus, COPD chronic obstructive pulmonary disease, SBP systolic blood pressure, DBP diastolic blood pressure, HDL high-density lipoprotein cholesterol, FBG fasting blood-glucose, LVEF left ventricular ejection fraction Table 4Treshold effect analysis of VAP-1 on MACE in patients with HFVAP-1(ng/mL)HR95% CIP value<13350.99930.9967–1.00190.5901≥ 13351.0631.06–1.066< 0.001Adjusted for Gender, Age, Af, CHD, Smoke, Neutrophil, Lymphocyte, hemoglobin, PLT, Scr, Bun, UA, eGFR, TG, TC, LDL, TBIL, IBIL, ALB, CK, CTnT, NTproBNP, D dimer, LAD, LVDD, HBP, IS, DM, COPD, Drink, SBP, DBP, heart rate, HDL, FBG, LVEF. Abbreviations: MACE major adverse cardiovascular events, HF heart failure, VAP-1 Vascular adhesion protein-1, Af atrial fibrillation, CHD coronary heart disease, Hb hemoglobin, PLT platelet, Scr serum creatinine, Bun blood urea nitrogen, UA serum uric acid, eGFR esti mated glomerularfiltrationrate, TG triglyceride, TC total cholesterol, LDL low density lipoprotein cholesterol, TBil total bilirubin, IBil indirect bilirubin, ALB serum albumin, CK creatine kinase, CTnT cardiac troponin T, NT-proBNP N terminal brain natriuretic peptide precursor, LAD left atrial diameter, LVDD left ventricular end-diastolic dimension, HBP high blood pressure, IS Ischemic stroke, DM diabetes mellitus, COPD chronic obstructive pulmonary disease, SBP systolic blood pressure, DBP diastolic blood pressure, HDL high-density lipoprotein cholesterol, FBG fasting blood-glucose, LVEF left ventricular ejection fraction Treshold effect analysis of VAP-1 on MACE in patients with HF Adjusted for Gender, Age, Af, CHD, Smoke, Neutrophil, Lymphocyte, hemoglobin, PLT, Scr, Bun, UA, eGFR, TG, TC, LDL, TBIL, IBIL, ALB, CK, CTnT, NTproBNP, D dimer, LAD, LVDD, HBP, IS, DM, COPD, Drink, SBP, DBP, heart rate, HDL, FBG, LVEF. Abbreviations: MACE major adverse cardiovascular events, HF heart failure, VAP-1 Vascular adhesion protein-1, Af atrial fibrillation, CHD coronary heart disease, Hb hemoglobin, PLT platelet, Scr serum creatinine, Bun blood urea nitrogen, UA serum uric acid, eGFR esti mated glomerularfiltrationrate, TG triglyceride, TC total cholesterol, LDL low density lipoprotein cholesterol, TBil total bilirubin, IBil indirect bilirubin, ALB serum albumin, CK creatine kinase, CTnT cardiac troponin T, NT-proBNP N terminal brain natriuretic peptide precursor, LAD left atrial diameter, LVDD left ventricular end-diastolic dimension, HBP high blood pressure, IS Ischemic stroke, DM diabetes mellitus, COPD chronic obstructive pulmonary disease, SBP systolic blood pressure, DBP diastolic blood pressure, HDL high-density lipoprotein cholesterol, FBG fasting blood-glucose, LVEF left ventricular ejection fraction Serum VAP-1 levels and HF risk Among the 336 enrolled individuals, we conducted a systematic investigation into the link between VAP-1 concentrations and heart failure occurrence. Through rigorous statistical modeling that included both single-variable and multi-variable analyses, we found that circulating VAP-1 concentrations served as a standalone prognostic factor for HF incidence (HR = 1.0012, 95% CI = 1.0001–1.0022, P = 0.0271; Supplementary Tables 3–4). Evaluation of predictive accuracy through ROC curve methodology revealed that VAP-1 showed fair discriminative ability for identifying individuals at risk of developing HF (area under the curve [AUC] = 0.671, 95% CI = 0.614–0.729, P < 0.0001). Supplementary Fig. 1A demonstrates that the most effective differentiation occurred when the threshold was set at 585 ng/mL (designated as the cutoff point), yielding a sensitivity rate of 56.4% alongside a specificity of 70.8%. NT-proBNP is recognized as a biomarker for HF diagnosis. Our investigation examined the prognostic potential of integrating VAP-1 with NT-proBNP for heart failure (HF) detection. The results revealed a higher efficacy in this combined approach compared to using NT-proBNP in isolation, although the difference was not statistically significant(AUC1 [NT-proBNP] versu AUC2 [NT-proBNP + VAP-1] = 0.972, 95% CI = 0.9574–0.986 vs. 0.973, 95% CI = 0.96–0.986, P = 0.491; Supplementary Fig. 1B). Discussion This longitudinal cohort analysis revealed that increased serum VAP-1 levels were positively associated with HF development across all subgroups. Importantly, the research established that higher circulating VAP-1 measurements serve as reliable indicators for MACE in HF patients. Through rigorous cutoff value assessment, the analysis determined that exceeding the 1335 ng/mL VAP-1 threshold corresponded to a 6.3% elevation in MACE likelihood. As the most comprehensive clinical evaluation conducted in recent years regarding VAP-1’s clinical utility, this investigation provides novel evidence about the biomarker’s diagnostic and predictive value for heart failure treatment. The results yield valuable clinical implications that could potentially improve treatment protocols and therapeutic approaches for heart failure patients. A 1997 investigation by Boomsma and colleagues revealed a correlation between increased VAP-1/SSAO concentrations in blood serum and the progression of HF [27]. Later in 2000, scientific evidence demonstrated that serum VAP-1/SSAO measurements could serve as an autonomous prognostic indicator for long-term survival in chronic HF patients [26]. It’s noteworthy that these research projects exclusively examined individuals suffering from moderate to advanced chronic HF (NYHA Class III-IV), all presenting with one or more cardiac structural abnormalities: LVEF below 35%, LVDD exceeding 6 cm, echocardiographic fractional shortening under 20%, or cardiothoracic ratio surpassing 50% on radiographic examination [30]. Subsequent research conducted by Claudia Marinho and her team in 2010 documented significantly higher serum SSAO levels in affected individuals when contrasted with healthy controls. The research involved participants diagnosed with HF and hypertensive cardiac conditions, exhibiting diminished LVEF (≤ 40%) and classified as NYHA Class II-IV [28]. Our data revealed a direct correlation between elevated serum VAP-1 levels and the risk of incident HF and MACE. This connection persisted when examined through multiple regression analyses. Kaplan-Meier analysis revealed a dose-dependent gradient in MACE risk among HF patients when stratified by serum VAP-1 concentration. Furthermore, threshold analysis in HF patients demonstrated a 6.3% rise in MACE probability when VAP-1 levels surpassed 1355 ng/mL, whereas no significant association was detected below this threshold. Unlike prior clinical studies, our cohort encompassed all HF subtypes without NYHA class or ejection fraction restrictions, employing current diagnostic standards. Moreover, the past decade has witnessed a paradigm shift in heart failure management, driven by deeper insights into its pathophysiology. This progress has led to a more refined therapeutic arsenal, enabling personalized strategies that significantly enhance patients’ quality of life and prolong survival. Consequently, there exists a critical need to reassess the diagnostic and prognostic significance of VAP-1 in relation to heart failure. When interpreting the prognostic value of VAP-1 in HF, it is essential to consider the complex pathophysiological milieu of HF, particularly the interplay between systemic inflammation and congestion. HF-associated congestion can exacerbate inflammation, a key driver of disease progression. This is supported by recent evidence showing that a congestion index and an inflammatory index are synergistic, independent predictors of mortality in acute HF [31]. Therefore, elevated VAP-1, a marker induced by inflammation and involved in leukocyte trafficking, may serve as an integrator of this adverse pathophysiological axis. Our identified threshold (1355 ng/mL) might thus identify a patient subset with a more active “congestion-inflammation” profile, explaining the higher MACE risk. Further research should correlate VAP-1 with direct congestion and inflammatory markers to clarify its specific role. Extensive research has demonstrated that VAP-1 exhibits significant correlations with multiple cardiovascular disorders and major adverse cardiovascular events across different patient groups. This evidence implies that VAP-1 could contribute to disease mechanisms in cardiac conditions including HF, owing to its distinctive biological properties. Expressed on endothelial cells, VAP-1 orchestrates​ the recruitment of leukocytes by supporting their adhesion to and subsequent transmigration through the vascular wall. In normal physiological states, this molecule predominantly localizes to intracellular vesicular structures. However, when exposed to inflammatory or other disease-related stimuli, these vesicles quickly move to and integrate with the plasma membrane. The sialic acid component of VAP-1 enables it to form stable covalent linkages with Siglec (sialic acid-binding Ig-like lectin) receptors present on leukocyte surfaces, consequently controlling their attachment and transmigration through vascular endothelium [32, 33]. The enzymatic action of VAP-1 on arginine residues within Siglec proteins produces hydrogen peroxide (H2O2), thereby triggering the generation of reactive oxygen species. Research has established VAP-1 as a pivotal​ regulator of inflammatory processes. Among leukocyte populations, two specific Siglec variants, namely Siglec-9 and Siglec-10, have been found to interact with VAP-1. Beyond facilitating cellular adhesion, VAP-1’s catalytic function stimulates the production of additional adhesion molecules, triggers specific signaling cascades, and enhances leukocyte-endothelial interactions [34]. Functioning as an amine oxidase, this enzyme mediates the breakdown of methylamines and propylamines, producing potentially harmful byproducts including reactive aldehydes (formaldehyde and acetaldehyde), H2O2 and ammonia [11]. Furthermore, emerging evidence indicates VAP-1’s involvement in metabolic regulation. Within adipose tissue, the SSAO activity facilitates the movement of glucose transporter 4 from cytoplasmic stores to the plasma membrane, influencing glucose absorption and metabolism in insulin-responsive cells [35]. Experimental data reveal that pharmacological inhibition of VAP-1 with semicarbazide reduces adipose tissue formation in murine models, implying that SSAO enzymatic activity contributes to lipid storage processes [36]. Thus, evidence suggests that VAP-1 orchestrates​ key pathways driving cardiovascular pathogenesis, notably by modulating inflammatory immunity, propagating oxidative damage, and impairing metabolic function. Presently, research exploring the function and precise pathways of VAP-1 in HF development remains scarce, and the conclusions remain inconclusive. Experimental evidence indicates that blocking VAP-1 activity reduces monocyte migration into surrounding tissues. Considering monocytes play a crucial role as inflammatory mediators during cardiac structural changes, this observation implies VAP-1 might enhance their movement into heart tissue, consequently accelerating cardiac remodeling processes [37]. Scientific reports demonstrate that VAP-1’s catalytic function elevates expression levels of multiple cell adhesion proteins (including VCAM-1, ICAM-1, MAdCAM-1, along with E- and P-selectins), stimulates associated molecular pathways, and encourages white blood cell attachment and penetration into heart muscle tissue [11]. Furthermore, VAP-1 could potentially intensify oxidative damage by breaking down specific compounds, trigger programmed cell death in cardiac cells, and contribute to myocardial remodeling. Studies have shown that VAP-1 knockout reduces myocardial oxidative stress following infarction, inhibits myocardial fibrosis, and improves myocardial remodeling [38]. These observations thus suggest that VAP-1 is implicated in​ both the onset and disease evolution of heart failure, as well as in the resultant cardiac structural alterations. However, additional investigations are necessary to validate these preliminary conclusions regarding its mechanistic involvement. To summarize, our research offers initial findings indicating that higher VAP-1 concentrations correlate with greater likelihood of developing HF and experiencing MACE. While this cohort investigation employed rigorous participant selection standards and accounted for multiple potential confounders, several constraints should be acknowledged. First of all, the recruitment of subjects from a single medical institution might have resulted in limited population diversity. Additionally, the observational design could have allowed for residual confounding from unaccounted variables, though we implemented comprehensive covariate inclusion and performed extensive statistical modeling to minimize such effects. Moreover, the relatively modest sample size \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\mathrm{n}=336$$\end{document} suggests that these findings warrant cautious interpretation and should be validated in broader cohorts. Lastly, the comprehensive collection and analysis of all-cause mortality data were limited as a consequence of the COVID-19 pandemic. Conclusions Our research demonstrates a notable correlation linking increased VAP-1 concentrations with heightened risks of developing HF and experiencing MACE. Additionally, the evidence indicates that VAP-1 may serve as a valuable indicator for the diagnosis and prognosis of heart failure. Supplementary Information Supplementary Material 1. Supplementary Material 1. Supplementary Material 2. Supplementary Material 2.